Skinvisible, Inc. SEC filings SKVI

Skinvisible, Inc. has 391 filings in SEC EDGAR's recent list, going back to Apr 30, 1999. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jan 23, 2025 (regulation fd disclosure). The company's fiscal year ends on December 31.

Skinvisible, Inc. SEC filings
Form Description Filed Period
10-K Annual report Mar 31, 2026 Dec 31, 2025
10-K Annual report Apr 14, 2025 Dec 31, 2024
10-K Annual report Apr 16, 2024 Dec 31, 2023
10-K Annual report Mar 30, 2023 Dec 31, 2022
10-K Annual report Mar 31, 2022 Dec 31, 2021
10-K Annual report Apr 15, 2021 Dec 31, 2020
10-K Annual report May 14, 2020 Dec 31, 2019
10-K Annual report Apr 15, 2019 Dec 31, 2018
10-K Annual report Mar 23, 2018 Dec 31, 2017
10-K Annual report Apr 17, 2017 Dec 31, 2016
10-K Annual report Apr 14, 2016 Dec 31, 2015
10-K Annual report Mar 31, 2015 Dec 31, 2014
10-K Annual report Apr 11, 2014 Dec 31, 2013
10-K Annual report Apr 16, 2013 Dec 31, 2012
10-K/A Amended annual report Nov 19, 2012 Dec 31, 2011
10-K Annual report Apr 16, 2012 Dec 31, 2011
10-K Annual report Apr 15, 2011 Feb 28, 2011
10-K Annual report Apr 15, 2010 Dec 31, 2009
10-K/A Amended annual report Feb 8, 2010 Dec 31, 2008
10-K Annual report Apr 15, 2009 Dec 31, 2008
10-K Annual report Mar 31, 2000 Dec 31, 1999

Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SKVI (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Las Vegas, NV
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1085277
Former names
SKINVISIBLE INC (until Aug 14, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.